From October 15th to 18th 2025, during BioPlus-InterPhex, the annual biopharmaceutical conference held in Seoul, South Korea, Leo Luo, Founding Partner of the Angine Bio as well as established "Health & Pharma Partner” Innovation Center, was invited to attend the event.
The closed-door discussion with Japanese and Korean industry experts on the conference format and topics for the "Asia Bio Connect" (ABC) summit, which will be held alternately in China, South Korea, and Japan in the coming years. Leo Luo was also honored to serve on the Asia Bio Connect planning committee in the next several years. The planned ABC summit will bring together leading biopharmaceutical companies, investment institutions, and policymakers from China, Japan, and South Korea for in-depth discussions and collaborations on topics such as policy coordination, innovative development, cross-border business development collaboration, and investment and financing in the Asian biopharmaceutical industry. The inaugural ABC will be held in South Korea in October 2026.
On the morning of October 18th, Leo Luo also participated in a roundtable discussion at the InterPhex conference with the topic of “the DeepSeek moment in China's biopharmaceutical industry”. Other panelists included a senior researcher at the Korea Institute for Industrial Economics and Trade, the chief representative of Kiwoom Securities Research, a representative from the US NewCo partner, and the head of investment at NOVO Holding. During the meeting, Leo engaged in an in-depth discussion with the panelists on the current development trends of China's biopharmaceutical industry, trends in BD collaborations, and the internationalization of innovative drugs.
As a cross-board BD and transactions solution company, Angine is committed to provide the professional solutions and investment incubation for the internationalization of innovative drug business and BD collaboration between China and other overseas markets. Angine Bio and established "Health & Pharma Partner" Innovation Center provide the “one-stop” comprehensive support to the clients served, from the formulation of internationalization and BD strategies, to the profiling and professional connections of potential international BD partners, and assisting to sign the BD collaboration agreements (In/Out). Angine team, along with its overseas partners and experts, believes that as the overseas ecosystem platform for "Health & Pharma Partner" matures and its service projects gradually land, it will be able to provide clients with more in-depth professional empowerment and services from both the "buy-side" and "sell-side" perspectives for a longer period of time. This will enable them to achieve greater success in both "innovation" and "internationalization" in a more pragmatic and practical manner.
If you want to know about "Health & Pharma Partner" Innovation Center as well as more deep information about landscape of China Pharma and Biotech as well as related generated innovation and BD transaction news, you can log into www.angineglobal.com for more information.